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Introduction: Prosthetic arteriovenous grafts (AVGs) in the lower extremity represent a useful alternative for hemodial-
ysis vascular access when all upper limb access sites have been used or in some patients when freedom of both hands is
necessary during dialysis. Reported complications include an increased risk of infection and limb ischemia. This study
evaluated our experience with the patency outcomes and complication rates of polytetrafluoroethylene (PTFE) AVGs
placed in the thigh.
Methods: A retrospective outcomes analysis was performed of all femoral AVGs inserted between January 1992 and July
2007. Data were obtained by review of medical records for patient demographics, comorbidities, and AVG-related
outcomes. Patency, complication rates, and risk factors for infection were determined.
Results: A total of 153 prosthetic AVGs were placed in 127 patients (63 men). Mean patient age was 52.7  16.3 years.
Median follow-up was 25 months (range, 1-169 months). The most common underlying renal disease was glomerulo-
nephritis in 27 (21%). Hypertension and coronary artery disease were common comorbidities, respectively, in 49 (39%)
and 23 patients (18%). The primary and secondary AVG patency rates at 12 months were 53.9% and 75.3%, respectively,
and 2- and 5-year patency rates were, respectively, 39.6% and 19.3% (primary) and 63.8% and 50.6% (secondary). The
mean AVG survival for all cases was 31.6 months (range, 0-149 months). Surgical thrombectomy was required in 82
(54%), and 22 AVGs (14%) required surgical revision for stenosis. Infection occurred in 41 AVGs (27%), and limb
ischemia occurred in 2 (1.3%). Statistical analysis did not reveal a significant risk factor for infection.
Conclusions: Femoral AVGs are a suitable alternative to upper limb vascular access, with acceptable primary and secondary
patency rates. Infection occurred in approximately one-quarter of cases, whereas steal was uncommon. (J Vasc Surg
2010;52:1546-50.)Reliable, functioning vascular access is a lifeline for
patients with end-stage renal disease who require hemodi-
alysis. According to the National Kidney Foundation Kid-
ney Disease Outcomes Quality Initiative1and the European
Best Practices Guidelines for Vascular Access,2 the first
choice of a dialysis access conduit is an autologous arterio-
venous fistula (AVF) in the lower or upper arm because
autologous vein AVFs offer long-term patency along with a
low risk of infection.
When no suitable veins are available or after exhaustion
of autologous options, a prosthetic AV graft (AVG) can be
used to establish permanent vascular access in the arm.
When there are no options for AVF in the upper extremi-
ties, an AVF can be created in the lower extremity. Sur-
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1546geons generally reserve access attempts in the lower ex-
tremities for situations in which all upper extremity options
have been exhausted. Disadvantages of femoral vascular
access include the risk of ipsilateral limb ischemia and a
higher reported incidence of infection with prosthetic AVG
of up to 41%3-7 compared with 9% in the upper limb.7
The aim of this study was to evaluate the use and
outcomes of prosthetic lower extremity AVGs at the Royal
Prince Alfred Hospital (RPAH), Sydney, New South
Wales, Australia. This unit is a tertiary center for vascular
access hemodialysis and has a relatively high proportion of
patients undertaking home hemodialysis. Home dialysis
requires the ability of patients to self-cannulate the dialysis
access conduit, which may also be a factor in establishing
vascular access in the lower extremity. The major advantage
of thigh AVG placement is the possibility for patients to use
both hands during dialysis sessions. This series expands on
the cohort previously reported by Khadra et al.5
METHODS
Patients. From January 1, 1992, until July 1, 2007,
171 polytetrafluoroethylene (PTFE) AVGs were opera-
tively placed in the lower extremity at the RPAH. The
analysis excluded 14 patients: 11 were lost to follow-up and
3 died within 30 days of AVG placement of causes unre-
lated to the access procedure. Four AVGs placed into the
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the analysis. Data analysis was performed on 153 AVGs in
127 patients using databanks from medical and vascular
laboratory records. The data obtained included patient
demographic characteristics, medical comorbidities, AVG
patency, and vascular access interventional procedures.
These data were used to calculate primary, primary assisted,
and secondary patencies after 1, 2, and 5 years. Also evalu-
ated were complications reported during the follow-up
period, including infection, stenosis, thrombosis, and isch-
emia caused by access placement. Patient follow-up was a
median of 25 months (range, 1-169 months).
Primary AVG patency was defined as the interval from
the time of AVG placement until any necessary intervention
to maintain normal AVG function or to re-establish pa-
tency. Primary assisted patency was the period from place-
ment until access failure, including interventions that were
undertaken to maintain access. Secondary patency was de-
fined as the time of patency measurement, including any
intervening surgical or endovascular actions designed to
re-establish functionality.8
The thigh AVGs were placed in a loop configuration
between the superficial femoral artery and the adjacent
superficial femoral vein in 135 of 153 procedures (88%). In
the remaining procedures, the long saphenous vein was
used as venous outflow or the common femoral artery was
used for the arterial inflow. A more detailed description of
the procedure is provided by Khadra et al.5 All AVGs were
made of non-heparin-bonded PTFE but came from differ-
ent manufacturers. The diameter of the grafts ranged from
6 to 8 mm, depending on the surgeon’s choice.
Statistics. Statistical analysis to determine influence of
risk factors for infection was performed with SPSS 16.0
software (SPSS Inc, Chicago, Ill). Kaplan-Meier survival
curves were generated in GraphPad Prism 5 software
(GraphPad Software, La Jolla, Calif). The influence of
gender, diabetes, and previous vascular access was exam-
ined with the 2 test, and influence of age with the Mann-
Whitney U test. Values of P  .05 were considered signif-
icant.
RESULTS
Patient characteristics are reported in Table I.Men and
women were equally represented in the study group (63
men, 64 women), and the mean age was 52.7 16.3 years.
The median patient follow-up was 25 months (range,
1-169 months).
The most common underlying causes of end-stage
renal failure were glomerulonephritis, analgesic nephropa-
thy, and diabetic nephropathy. Hypertension was present
in 49 patients and was the most commonly reported co-
morbidity (39%), whereas diabetes mellitus was present in
21 patients (17%). The percentage of patients who had
previously undergone vascular access procedures was high
(n  100, 79%).
The Kaplan-Meier survival curves for primary and sec-
ondary AVG patency are shown in Figs 1 and 2, respec-
tively. Primary graft failure, defined as AVG failure 30days after placement, occurred in eight grafts (5.2%; Table
II). The mean AVG survival was 31.6 months (range,
0-149months). Primary AVG patency and primacy assisted
patency after 1 year were both 53.9%; however, secondary
patency at 1 year was 75.3%. The 2-year primary and
secondary patency rates were 39.6% and 63.8%, respec-
tively, and the 5-year primary and secondary patency rates
were 19.3% and 50.6%, respectively (Table II).
The most frequently reported complication of AVG
was thrombosis, and a thrombectomy was required in 82
AVGs (54%; Table III). A surgical revision for a stenosis was
also required in 22 AVGs (14%). Endovascular repair was
Table I. Patient characteristics
No. (%)
Variable or mean  SD
Patients 127
Age, year 52.7  16.3
Gender
Male 63
Female 64
Cause renal failure
Glomerulonephritis 34 (26)
Analgetic nephropathy 13 (10)
Diabetic nephropathy 13 (10)
Vascular nephropathy 10 (8)
Polycystic kidney disease 10 (8)
IgA nephropathy 8 (6)
Reflux nephropathy 7 (6)
Autoimmune 7 (6)
Diverse 23 (18)
Comorbidity
Hypertension 49 (38)
Coronary artery disease 23 (18)
Diabetes mellitus 21 (17)
Previous vascular access 100 (79)
IgA, Immunoglobulin A; SD, standard deviation.
Fig 1. Kaplan-Meier survival curve is shown for primary patency
of polytetrafluoroethylene arteriovenous grafts placed in the thigh.not part of the routine treatment protocol during the
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Pseudoaneurysms requiring an intervention were seen in
11 AVGs (7%).
Clinically significant infection occurred in 37 patients
(29%) with an AVG, defined as grade II severity according
Fig 2. Kaplan-Meier survival curve is shown for secondary pa-
tency of polytetrafluoroethylene arteriovenous grafts placed in the
thigh.
Table II. Patency rates
Variable %
Primary graft failure 5.2
Primary patency
1 year 53.9
2 years 39.6
5 years 19.3
Primary assisted patency
1 year 53.9
2 years 39.6
5 years 19.3
Secondary patency
1 year 75.3
2 years 63.8
5 years 50.6
Table III. Major graft complications
Total grafts
Complication No. (%)
Thrombosis/significant stenosis 110 (72)
Requiring thrombectomy 82 (54)
Requiring surgical revision 22 (14)
Endovascular treatment 6 (4)
Infection 41 (27)
Graft excision and replacement 15 (17)
Total graft removal 26 (10)
Pseudoaneurysms 11 (7)
Steal syndrome 2 (1)to the Society for Vascular Surgery/American Associationfor Vascular Surgery standards,8 plus another 4 patients
sustained infection in their second AVG. The overall AVG
infection rate was therefore 27% (n  41). Infections that
were adequately treated by antibiotics, without surgical
drainage or revision, were regarded as minor and were
excluded from this analysis. Surgical removal of the entire
AVG was required in 26 of 41 cases (63%). Three patients
who required total AVG removal also underwent a sartorius
flap procedure to cover the femoral vessels. In the remain-
ing 15 infected AVGs (37%), salvage of the vascular access
was achieved by means of partial excision of the infected
section and interposition bypass grafting. One additional
interposition procedure was performed after 57 days be-
cause of progressive infection.
Two patients died of cardiac complications 30 days
after management of the infection. There was no limb loss
due to infection. The analysis of the possible effect of
patient factors on AVG infection (Table IV) revealed no
significant correlation between the occurrence of infection
and gender, age, underlying comorbidities, or having un-
dergone previous vascular access (P  .05).
Only two patients (1.6%) in our series had signs or
symptoms of impaired ipsilateral limb arterial circulation.
One patient was managed bymeans of operative tapering of
the AVG to diminish the steal. The other patient required
manual compression of the AVG to facilitate rapid AVG
thrombosis/occlusion after presenting with critical isch-
emia of the toes. The patient required below knee amputa-
tion 6 months later due to progression of medial calcific
peripheral arterial disease.
DISCUSSION
Although the upper extremity remains the favored lo-
cation for vascular access, thigh AVGs are still an option in
some patients, as reported in the literature, when upper arm
sites have been exhausted.3,7 To our knowledge, this is the
largest reported series of thigh AVGs. The 1-year primary
and secondary patency rates of AVG in this series of 53.9%
and 75.3%, respectively, are comparable with other series
that have recently reported primary and secondary patency
rates for PTFE thigh AVG after 1 year of 34% to 71% and
68% to 83%, respectively.3,9,10
Secondary endovascular AV procedures at the RPAH
have usually been done only on autogenous fistulas. Be-
Table IV. Risk factors for graft infection
No infection Infection P
Variable No. (%) No. (%)
Age, mean rank 63.7 64.7 .89a
Male gender 46 (51.1) 17 (45.9) .60
Diabetes mellitus 17 (18.9) 4 (10.8) .27
Hypertension 42 (46.7) 18 (48.6) .84
Coronary artery disease 19 (21.1) 4 (10.8) .17
Previous vascular access 74 (66.0) 26 (63.0) .14
aMann-Whitney U test.cause we performed few endovascular treatments during
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in primary patency in this series compared with published
reports of 34% to 71%,3,9-11 although our AVG patency
rate is comparable with the 71% patency rate of Tashjian et
al.9 Also, because varying methods of reporting AVG pa-
tency have been used, it is not possible to accurately com-
pare our AVG patency rates with series reported by Khadra
et al,5 Korzets et al,6 Taylor et al,11 or Bhandari, et al.12
Miller et al7 reported the outcomes of thigh AVGs com-
pared with upper arm fistulas, but reported the median
intervention-free and thrombosis-free intervals instead of
AVG patencies after 1 year. A large multicenter study also
reported that the primary patency for forearm prosthetic
grafts was 44% and the secondary patency amounted to 79%
after 1 year.13 Thus, the patency rates for thigh AVG in this
study are comparable to these published results. They are
also comparable to the weighted mean primary patency of
48% and the secondary patency of 69% in thigh dialysis
access conduits in the recently reported meta-analysis by
Antoniou et al.10
Of note in the earlier reported experience at the RPAH,
the mean AVG survival time after exclusion of patients who
died or received a transplant with a functioning AVG was
99.8 weeks (24.9 months).5 In the current series with the
overall mean AVG survival time of 31.6 months, there
seems to have been a slight improvement in AVG outcome
during the last decade.
The prevalence of clinically significant infection in our
study group was 27%, which is comparable to the 5% to 41%
prevalence in other reports.3-7 Infection remains the most
common reported complication after thigh AVG place-
ment, and this complication is one of the major reasons
upper arm AVGs are favored in vascular access guide-
lines,1,2 In the series byMiller et al,7 access loss as a result of
infection was 11.% for thigh AVGs vs 5.2% for upper arm
grafts. This is similar to our series, where 26 AVGs (17%)
were lost due to significant infection, which is similar to
that reported in the meta-analysis by Antoniou et al.10
The ability to salvage 15 (37%) of the infected AVGs by
means of partial excision and insertion of an interposition
graft meant we could prevent loss of the access site and
dialysis could be continued without the longer-term need
for a tunneled dialysis catheter. This approach has been
reported by Ryan et al,14 who documented a successful
outcome with this technique for infected upper arm AVG
in 17 of 23 cases (74%). Cull et al3 also reported segmental
resection for salvage of infected grafts, but not the overall
success rate. The report by Schwab et al15 on this approach
included three thigh AVGs.
Also of importance for infected thigh AVG was the
application of sartorius muscle flap transposition16 in three
cases to cover the femoral vessels to protect the vessels from
further infection, which can eventually lead to limb loss.
Sartorius muscle transposition has been described in the
setting of infection related to femoral vessels after other
vascular surgical procedures.16
Within the setting of vascular access for hemodialysis,
infection is a known major problem, accounting for 15% ofdeaths of end-stage renal disease patients.17 Most infec-
tions are caused by Staphylococcus aureus18 and bacteremia
is frequent. Because the proximal thigh AVG is located near
the groin, bacterial contamination is more likely to oc-
cur.7,19 The patient mortality rate of 2 of 127 (1.5%)
related to the preceding requirement for surgical manage-
ment of an infected AVG in this series is lower than the 4%
reported by Cull et al.3
Apart from the risk of systemic sepsis with AVG infec-
tion, loss of the access is also a major complication. In our
series, 26 AVGs had to be abandoned because of infection,
with the patients having to receive dialysis using alternative
methods and subsequently undergoing further access pro-
cedures; however, no patient died due to lack of dialysis
access.3
Impaired ipsilateral limb arterial circulation is the other
major complication seen with the use of thigh AVGs. This
condition was seen in only two cases (1.6%) in our series,
which is lower than the incidence of ischemic complications
of 7.18% in a recent meta-analysis.10 The discrepancy in
incidence of ischemia might be related to our relatively
young group of patients (mean age, 52.7 years) and stricter
patient selection. Patients who showed signs of peripheral
arterial disease on clinical examination were generally not
eligible for thigh AVG insertion, and when doubt existed,
duplex ultrasound imaging of the distal arterial tree was
performed. The result of this very strict selection of patients
might explain the low incidence of ipsilateral limb ischemia
in our series. This practice is a continuation of that reported
in the earlier study of Khadra et al5 at the RPAH. This
approach is alsomentioned byMiller et al,7 where there was
also careful evaluation of the lower extremity before thigh
AVG placement, and no ischemic complications were re-
ported.
Although our study contains the largest number of
femoral AVG cases and a long follow-up period, we realize
that graft materials and endovascular techniques have
evolved during this period, which is a disadvantage of our
analysis. More frequent use of endovascular interventions
might improve the patency of femoral AVGs in the future.
Considering the acceptable patency rates but the
higher infection risk compared with upper limb AV access,
we believe that upper thigh AVGs are an established third-
choice option for vascular access after exhaustion of fore-
arm and upper arm access locations. Gradman et al20 also
showed reasonable outcomes with autologous lower ex-
tremity AVFs by means of femoral or saphenous vein trans-
position. In their initial experience, however, steal syn-
drome occurred in 8 of 25 patients, which could be
improved by intraoperative tapering and different patient
selection.21
The current alterative for most patients who are candi-
dates for femoral vascular acces is a permanent cuffed
central venous catheter, which is not a durable long-term
solution. According to the European Best Practice Guide-
lines for Vascular Access,2 femoral access should be per-
formed before choosing a central venous catheter. The
reported relative risk of bloodstream infection can be sig-
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pared with AVGs (8.49% vs 1.47%).22 Lee et al23 also
emphasized the need to confine the use of catheters, re-
garding their calculated number of 2.6 to 3.2 catheter-
related infections per 1000 catheter days. Also, patient
mortality, reported as the 1-year crude death rate by Xue et
al,24 was 41.5% for catheters and 28.1% for synthetic grafts.
CONCLUSIONS
The patency rates in this large series of femoral AVGs
are acceptable, and the complication rates of infection and
steal are comparable to those reported in the literature,
with a low incidence of lower limb ischemia. We conclude
that femoral AVGs offer a satisfactory alternative for pa-
tients who are not good candidates for upper limb vascular
access.
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